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What is already known about the topic? 
 Childhood atopic dermatitis is a costly disease for society. However, comprehensive 
cost estimations are lacking.  
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What does this study add? 
 This study comprises a health economic evaluation assessing different levels of care 
and includes various categories of costs. 
 The result showed that informal caregiving was the most prominent cost for children 




Background: Childhood atopic dermatitis can often have a negative impact on quality of life 
for affected children and their caregivers. The condition contributes to increased healthcare 
costs and can pose heavy economic burdens on healthcare systems and societies.  
 
Objectives: The objective of this study is to provide a comprehensive estimate of the 
economic burden of childhood atopic dermatitis in a Singaporean sample and to investigate 
associated factors.  
 
Methods: This cross-sectional cost-of-illness study applied a societal perspective. Data was 
collected between December 2016 and December 2017 in Singapore. Caregivers to children 
below 16 years of age with physician-confirmed diagnosis of atopic dermatitis were recruited 
and socio-demographics, clinical characteristics, health service utilisation data and time spent 
on caregiving were collected from all eligible participants. 
 
Results: The average annual cost per child with atopic dermatitis was estimated at US$7,943 
(mild US$6,651, moderate US$7,935 and severe US$14,335) in 2017 prices. The major cost 
was for informal caregiving (46% of the total cost) followed by out-of-pocket expenses 
(37%). Healthcare utilisation contributed to 17% of the total cost of which 43% was for 
medications.  
 
Conclusions: Childhood atopic dermatitis imposes substantial costs with a large proportion 
arising from informal caregiving and out-of-pocket expenses. The cost for atopic dermatitis is 
also strongly related to disease severity. This information is important for policymakers and 
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BACKGROUND 
Atopic dermatitis (AD), or eczema is a common chronic inflammatory dermatosis 
characterised by recurring exacerbations of red, dry and itchy skin (1). International estimates 
from a 2009 study showed a global prevalence of 0.9% to 22.5% for children aged 6-7 years; 
and between 0.2% and 24.6% for children aged 13-14 years (2). The prevalence of childhood 
AD in Singapore has remained high but stable over time, with a prevalence of 17.9% to 
22.7% in a 2002 study compared to 20.6% in year 2018 (3, 4). AD often affects every day life 
as it commonly requires regular treatments to repair the skin barrier (e.g. moisturisers), 
avoidance of environmental triggers, and topical anti-inflammatory management (topical 
corticosteroids or calcineurin inhibitors) to control the inflammation (1, 5). The condition 
reduces health-related quality of life (HRQoL) for children and their parents (6-9). Children 
often suffer from severe itching leading to subsequent sleep disturbances affecting both them 
and their caregivers (7, 8). AD can have a negative effect on the child’s psychosocial life 
because of their physical appearance and inability to take part in social activities such as 
swimming (6, 10). They are also often ostracised, bullied and isolated from their peers (6, 
10). Childhood AD places substantial economic burden on families and societies as well (11, 
12), with cost estimates varying between countries, study designs, included cost components 
and disease severity (6, 11, 13). In the Asia Pacific region, the economic burden of childhood 
AD is higher in developed countries such as Australia, South Korea and Singapore (range 
US$1,000 to US$6,000 per patient per year) compared to less developed countries (range 
US$199 to US$743 annually) (14). Previous studies have estimated the healthcare costs of 
AD in Singapore at US$4,753 annually per child, with US$1,097 being costs for healthcare 
visits and treatments (15, 16). However, these costs are speculative estimates as there have 
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childhood AD presents varying annual cost-estimates per child ranging between US$71 and 
US$4,389 in Europe and the United States (12, 13, 17-19). It should however be noted that 
studies include different cost components and study populations, when estimating the costs 
and thereby preventing direct comparisons. 
Healthcare in Singapore comprises of a government-run public healthcare system and a 
private healthcare sector. Healthcare is financed through a combination of direct government 
subsidies, compulsory savings, national healthcare insurance, cost sharing and optional 
private insurance. The proportion of direct government subsidies is dependent on socio-
economic status of patients. 
The primary aim of this study is to provide a comprehensive estimate of the economic burden 
of childhood AD by assessing healthcare costs, costs for informal caregiving and other 
financial expenses for the family. We also aim to investigate associations between costs and 
socio-demographics as well as the severity of AD. 
 
METHODS 
Study design and participants 
This cross-sectional cost-of-illness study explored the cost of childhood AD from a societal 
perspective. Children below 16 years of age with a physician-confirmed diagnosis of AD 
were recruited from two public healthcare service providers in Singapore- an outpatient 
dermatology clinic in a tertiary paediatric hospital (KK Women’s & Children’s Hospital) and 
a speciality centre for skin diseases (National Skin Centre). Data were collected from all 
eligible children and caregivers who consented to take part in the study between December 
2016 and December 2017. Children with no legally authorised representative (LAR) who 
could give consent to enrol in the study and patients with a non-physician asserted diagnosis 
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Instrumentation and costing valuation for cost-consequences of childhood AD 
A modified version of the Client Service Receipt Inventory (CSRI) captured caregiver-
reported retrospective data imposed by childhood AD on healthcare service utilisation, 
medications, informal caregiving, out-of-pocket expenses, and cost for transportation to 
healthcare visits (20, 21). The total societal cost was calculated as the sum of all costs. Costs 
were reported in Singapore dollars (SGD) and attributed to the cost year of 2017, with prices 
adjusted by the Singapore consumer price index (healthcare component) for the same year 
when appropriate (22). Singapore dollars were converted into United States dollars (USD) 
using purchasing power parity rates from the World Bank’s international database (23). No 
discounting was applied since the study only assessed annual costs. 
Conservative assumptions were made throughout the study so as not to overestimate the 
burden of AD, e.g. when valuing costs, and in the process of entering the data when 
information was inadequate or incomplete.  
 
Healthcare service costs and cost for medications 
Costs for healthcare service utilisation comprised healthcare services from different levels of 
care (e.g. primary care, hospital care etc.) related to the child’s AD. The numbers of 
healthcare visits were linked to unit costs for specified services obtained from collaborating 
hospitals and other sources (24). Medication usage (including food supplements and 
complementary medicines) was reported by the caregiver stating medication/type of 
medication and dosage/frequency. Unit costs for medications were retrieved from one of the 
collaborating hospitals pharmacy and the average cost per category was calculated for each 
medication. 
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for transportation was made assuming a return trip for each visit, and based on unit costs for 
public transport, taxi or use of private vehicles (25-27). For inpatient hospital admissions, 
transportation calculations were made with the assumption that parents visited their child 
every second day. The annual cost of transportation was derived from the number of visits 
multiplied by the unit costs for the reported mode of transportation.  
 
Informal caregiving 
Informal caregiving included care that parents provided in caring for the child’s AD based on 
pre-set activities- personal care, preparing special meals due to dietary restrictions and 
providing emotional support. Time spent on personal care and specially-prepared homemade 
food, without noted duration, was assumed to be 5 minutes and 30 minutes per session, 
respectively.  Informal caregiving was valued as an opportunity cost where one hour of 
caregiver leisure time lost was assumed to be equivalent to 35% of the average per hour gross 
salary (28, 29). The annual cost for informal caregiving hours was calculated by the average 
hours of support given per week multiplied by the number of weeks in a year. 
 
Family expenses  
Out-of-pocket expenses for the family included cost for services or products used or 
purchased, e.g. moisturising creams, hygiene products, laundry costs due to the child’s AD. 
Moisturisers are included as part of family expenses as these are pharmacy retail items and 
not subsidised by the healthcare system. Costs for family expenses were reported as a weekly 
cost per item and converted into an annual cost. For items with a one-time cost, such as a 
humidifier, water filter and vacuum cleaner, the costs were converted to a yearly cost based 
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Assessment of severity level of AD 
Severity of the child’s AD was assessed by the treating physician and retrieved from medical 
records. Physicians at both study sites ascertained the severity of AD by using the modified 
physician global assessment (PGA) (30). 
 
Ethical considerations 
This study was approved by the Institutional Review Board of the National Healthcare Group 
(NHG-DSRB: 2015/01228) and Nanyang Technological University, Singapore (NTU IRB: 
IRB-2016-10-059-01). Caregivers and children received verbal and written information about 
the purpose of the study and that participation was voluntary before giving consent to 




This study reported means with standard deviation (SD) for continuous variables, and 
frequencies with corresponding proportions for categorical variables. Skewed variables were 
presented as median and range (min–max). Normality of continuous variables was assessed 
by Kolmogorov-Smirnovand Shapiro-Wilk test. Costs by AD severity (mild, moderate, and 
severe) were compared using Kruskal-Wallis H-test, and categorical variables were compared 
using Chi-square or Fisher’s exact test. Spearman’s rank correlation was used to assess the 
relationship between cost and continuous predictors such as disease duration and age. 
Relationships between total cost, socio-demographics and severity of AD were analysed by 
univariable and multivariable generalised linear model (GLM). As the total cost was strictly 
positive and heavily skewed to the right, we used gamma family with and log link function to 
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family within the GLM approach. Predictors are reported as log coefficients with 
corresponding standard errors (SE). The goodness-of-fit was assessed by two diff erent 
statistics, the deviance and the Pearson χ
2 
statistic. The mean predicted total cost by AD 
severity was also estimated. In cases of missing or incorrect data (e.g. unrealistic values), the 
participant was excluded from further analysis for that specific variable. All statistical 
analyses were performed using Stata statistical software version 14.2 (StataCorp LLC, 





Out of 735 eligible caregivers, 176 declined to participate in the study due to various reasons 
e.g. time constraints, language (English) deficiency, or if the caregiver not being the LAR of 
the child. A total of 559 caregivers and children with AD were recruited for the study (Table 
1).  
The average age was 6.6 (±4.6) years with a mean AD duration of 3.5 (±3.6) years. Most 
children were of Chinese ethnicity (72.5%), followed by Malay (16.0%), Indian (5.9%) and 
“other” (5.6%) ethnicities. This racial distribution fairly reflects the racial distribution of 
Singapore in general (31). Approximately half of the responding caregivers were university 
graduates (49.2%), followed by post-secondary or polytechnic (32.4%), and secondary school 
and lower (18.4%) qualifications. This generally reflects the educational levels of the 
similarly aged population in the country (32). The majority of families lived in government 
flats (77%), which is not necessarily related to socioeconomic status (31, 33), while 23% 
lived in condominiums or landed properties. This distribution is also reflective of the general 
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residents resides in public housing in Singapore (33). Clinician assessed severity of AD could 
only be retrieved for 513 participants and therefore, 46 participants were excluded from the 
analysis by severity. Most of the children had mild AD (61.6%), followed by moderate 
(25.5%), and severe (12.5%) AD. 
 
AD related healthcare service utilisation  
The mean total cost for healthcare service utilisation across all degrees of AD severity was 
US$1,349 per child per year (Table 2). The cost for medications accounted for 42.6% 
(US$574) of the total cost for healthcare utilisation, followed by specialist outpatient services 
accounting at 30.6% (US$413), while the remaining 26.8% comprised inpatient-, accident 
and emergency-, general practitioner and polyclinic, and other care, as well as transportation 
to healthcare visits. The most frequently used medications were topical and oral steroids 
(used by 57.7%) followed by antihistamines (25.0%) and combination creams (15.0%) 
(Supplementary Table 1). Topical- and oral steroids accounted for the highest cost, due to its 
widespread use, estimated at US$252 (43.9% of the total cost for medications); followed by 
calcineurin inhibitors at an average cost of US$150 (26%) per patient per annum. 
Less than 5% of the sample required inpatient treatment for AD, accounting for an average 
cost of US$164 per patient annually. Nearly all participants (99%) had incurred costs for 
transportation for healthcare visits, amounting to US$94 per patient per year.  
The severity of AD significantly impacted the total healthcare cost with mild AD at 
US$1,062, moderate AD at U$1,217 and severe AD at US$3,035 (p<0.001) per child per 
annum. Thus, the cost for severe AD is almost two and a half times the cost compared to 
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Informal caregiving  
As many as 91.6% of the caregivers reported spending an average of 10.3 hours of time each 
week providing informal caregiving due to their child’s AD (Table 3). Most caregivers 
reported that the largest proportion of time was spent on providing personal care for the child 
e.g. application of moisturisers (87.7%, estimated cost US$1,625 per patient per annum) and 
preparation of specially-made foods due to diet restrictions (51.1%, estimated at US$600 per 
patient per annum), as well as to accompany and to provide emotional support (42.3%, 
estimated cost US$1,217 per patient per annum) to the child. The average total cost for 
informal caregiving amounted to US$3,659 per child per year (Table 2). Analysing informal 
caregiving by severity showed that parents caring for children with mild, moderate and severe 
AD spent an average of 9.2 (estimated to cost US$3,244 per patient per year), 10.8 
(US$3,801 per patient per year) and 15.2 (US$5,395 per patient per year) hours (p= 0.019) 
respectively per week, hence establishing that the cost of informal care in severe AD is 1.4 to 
1.7 times more than mild and moderate disease.  
 
Out-of-pocket expenses  
Most caregivers (92.2%) reported out-of-pocket expenses to treat their child’s AD at an 
average of US$2,935 per child per year (Table 2). Moisturisers accounted for the highest out-
of-pocket expenses at US$1,084 per child per year (purchased by 90.3% of participants). 
Spending on hygiene products accounted for the second most costly out-of-pocket cost at 
US$648 (purchased by 78.6% of participants) per child per annum. Analysing out-of-pocket 
expenses by AD severity revealed significant differences between mild AD (US$2,344), 
moderate AD (US$2,908) and severe AD (US$5,906) (p<0.001). Out-of-pocket expenses for 
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Total financial cost  
The average cost for the total sample including all cost categories amounted to US$7,943 per 
child per year (Table 2). Stratified by severity, the cost for a child with mild AD was 
estimated at US$6,651, for moderate AD US$7,935, and US$14,335 for severe AD (p<0.001) 
per patient per annum. The total cost for a child with severe AD was greater than two times 
the cost for a child with mild or moderate condition. An increased cost for more severe AD 
was seen in all cost categories, especially for healthcare expenditure, but also for informal 
care and out-of-pocket expenses.   
 
Multivariable regression analyses  
Factors associated with the total cost for children with AD using multivariable generalised 
linear model are presented in Table 4. The multivariable analysis identified  significant 
factors associated with increasing cost as being of Malay ethnicity (coef.: 0.31, SE: 0.12, 
p=0.010)  or “other ethnicity” (coef.: 0.42, SE: 0.15, p=0.005) compared with the Chinese 
ethnic group; having a longer duration (years) of AD (coef.: 0.07, SE: 0.02, p<0.001), and 
moderate (coef.: 0.28, SE: 0.11, p=0.007) or severe (coef.: 0.94, SE: 0.16, p<0.001) AD. The 
age of the child was also statistically associated with the total cost (coef.: -0.07, SE: 0.09, 
p<0.001). Goodness-of-fit statistics showed that the model was of moderate fit overall. The 
mean adjusted total societal costs (±SE) per year was US$6,602 ± US$404 for mild AD, 
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Discussion 
The average total annual cost per child with AD was conservatively estimated at US$7,943 in 
our study which is substantially higher when compared to estimates from other countries e.g. 
the United States US$3,288 and Italy US$1,540 (17, 19). Findings from our study also show 
that the larger proportion of the overall costs for childhood AD were attributed to informal 
caregiving and out-of-pocket expenses rather than actual healthcare costs, strongly suggesting 
that the cost of caring for a child with AD goes far beyond the expenditures on actual 
healthcare. These findings add new insights as costs for informal caregiving that generally 
have not been comprehensively assessed in previous studies of childhood AD, highlighting 
the so far unknown socioeconomic burden of the condition. Previous health economic studies 
assessing costs for childhood AD included the cost for loss in productivity for parents but did 
not include costs for informal caregiving (19, 34). Including the cost of informal caregiving 
in cost-of-illness studies is crucial since some diseases, such as childhood AD, are associated 
with rather substantial time costs due to caregivers’ involvement in their child’s daily skin 
care (35). The average time spent on informal caregiving for childhood AD is comparable 
with other chronic diseases such as caring for an elderly person with diabetes (36), and 
should in consequence impact healthcare economic policies. 
In accordance to previous studies, we found that out-of-pocket expenses was the second 
highest cost factor in caring for childhood AD (7, 18).This again is important for 
policymakers to address since personal expenses, accelerated by the potentially long duration 
of disease can lead to financial strain for families, especially those with lower incomes (37). 
Increased awareness about the condition’s impact on the cost burden for affected families 
informs policy makers to divert resources for developing more efficient treatment options. 
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especially for moderate to severe conditions and that efficiency gains can be made by 
improved outpatient management. A better disease management of AD on an outpatient level 
could also minimise costly inpatient care. Recommendations from a governmental level 
should consider healthcare subsidies for affected families, better provision of support to 
informal caregivers and to use national healthcare insurances to pay for outpatient costs. We 
also suggest that AD should be included in the chronic disease management program 
(CDMP) to acknowledge the burdens and subsequent costs that the condition imposes. 
In alignment with other studies, our study found that severe AD is associated with greater 
costs compared to mild and moderate AD (18, 38). With optimal treatment, patients with 
moderate or even severe AD can improve significantly, leading to a possible overall 
reduction in cost, emphasizing the need for proper education of AD patients and their 
caregivers to improve compliance and outcomes. In addition, we also found significant 
differences in total cost due to ethnicity with Malay origin having a lower total cost. This 
may be due to socio-economic differences impacting healthcare seeking behaviour and out-
of-pocket expenses, or even genetic heritage related to degree of severity. These findings 
were unexpected and not at focus when designing the study but calls out for further research. 
Using a cost-of-illness approach allows us to understand the distributive efficiency and equity 
aspects of the disease burden of AD by generating information for policy and prioritisation as 
it addresses cost-driving components (39, 40).    
 
Limitations  
Limitations of the study include the self-reporting of healthcare utilisation, possibly 
introducing recall bias (41). Furthermore, there was no control group (healthy children 
without AD) in the study to provide a comparison of the incremental disease burden. Several 
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and data entry, which may have underestimated the real costs since a conservative approach 
was applied to not overestimate the costs. There is also likelihood that the surveyed patients 
attended the clinic due to an exacerbation and were potentially more severely affected by 
their AD compared to children with AD cared for solely by primary care clinics. This may 
possibly reflect a higher cost and affect the overall result. Furthermore, as we used a cross-
sectional study design, our conclusions do not reveal more long-term costs. Lastly, our use of 
convenient sampling approach may have excluded non-healthcare seeking caregivers of 
children with AD introducing a selection bias since this subgroup of patients were not 
represented in the study.  
 
Conclusion  
Childhood atopic dermatitis imposes substantial costs with a large proportion arising from 
informal caregiving and out-of-pocket expenses. The cost for AD is also strongly related to 
disease severity. This information is important for policymakers and other health planners 
when considering how to better support affected families. 
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Table 1. Socio-demographic and clinical profile of children with atopic dermatitis 
Characteristics (N = 559) Mean ± SD / n % 
Age in years 6.6 ± 4.6 - 
Diagnose duration in years (n = 550) 3.5 ± 3.6 - 
Gender   
Female  277 49.5 
Male  282 50.5 
   
Ethnic group (n = 557)   
Chinese 404 72.5 
Malay 89 16.0 
Indian 33 5.9 
Other 31 5.6 
   
Severity (n = 513)
*   
Mild 316 61.6 
Moderate 133 25.9 
Severe 64 12.5 
   
Responder's relation   
Mother  398 71.2 
Father  158 28.3 
Other  3 0.5 
   
Responder's qualification    
Secondary school or lower 103 18.4 
Post-secondary or polytechnic 181 32.4 
University 275 49.2 
   
Responder's employment status   
Employed  452 80.9 
Unemployed  107 19.1 
   
Accommodation type (n = 557)   
1-3 bedroom HDB-flat 68 12.2 
4-5 bedroom HDB-flat 361 64.8 
Condominium/landed property 128 23.0 
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Table 2. Annual average costs (US$) for healthcare, informal caregiving and out-of-pocket expenses for children with atopic dermatitis  
Type of health care utilisation 




Mild (n = 316) Moderate (n = 133) Severe (n = 64) 
% 
users 
Mean ± SD 




Mean ± SD 




Mean ± SD 




Mean ± SD 
Median (min - 
max) 
Healthcare service utilisation  
             
Inpatient care 4.7 
163.6 ± 
1239.8 





0.0 (0.0 - 17559.6) 3.8 48.1 ± 282.0 0.0 (0.0 - 2615.0) 17.2 
779.4 ± 
2602.3 




0.0 (0.0 – 
1175.5) 
3.8 8.1 ± 42.0 0.0 (0.0 - 391.8) 9.8 26.5 ± 89.2 0.0 (0.0 - 587.7) 14.1 67.3 ± 213.0 0.0 (0.0 - 1175.5) <0.001 




















395.2 (233.4 - 
9146.5) 
<0.001 
GP/ polyclinic services 45.2 
80.5 ± 
149.1 
0.0 (0.0 – 
1241.9) 
42.4 69.8 ± 133.3 0.0 (0.0 - 1241.9) 45.9 77.6 ± 131.6 0.0 (0.0 - 800.7) 57.8 139.6 ± 226.6  80.1 (0.0 - 1240.2) 0.024 
Other health services* 1.4 
4.0 ± 
48.0 









336.2 (0.0 –4109.5) 81.2 
596.9 ± 
818.5 





672.4 (0.0 - 
3979.7) 
<0.001 
Transportation  99 
93.8 ± 
127.2 
56.2 (0.0 – 
1506.8) 
99.1 78.9 ± 80.4 49.4 (0.0 - 647.4) 98.5 89.7 ± 101.3  58.8 (0.0 - 741.7)  100 176.1 ± 264.0  98.8 (5.1 - 1506.8) <0.001 
Total 100 
 1348.9 ± 
1862.9 















1470.3 (267.5 - 
20090.4) 
<0.001 
Informal care  
             
Personal care 87.7 
1625.1 ± 
2662.0  















1063.0 (0.0 - 
29764.9)  
0.202 










0.0 (0.0 - 9787.0) 39.1 
267.0 ± 
1027.0 
0.0 (0.0 - 9567.3)  50 216.0 ± 429.2 3.4 (0.0 - 1962.5) 0.027 










0.0 (0.0 - 19843.3) 51.1 
1257.1 ± 
2493.7 





0.0 (0.0 - 39686.5) 0.040 










0.0 (0.0 - 25512.8) 19.5 
524.9 ± 
1425.6 
0.0 (0.0 - 9921.6) 26.6 
594.3 ± 
1327.1 
0.0 (0.0 - 7441.2) 0.573 





0.0 (0.0 – 
4960.8)  
1.3 19.4 ± 282.5  0.0 (0.0 - 4960.8) 2.3 
20.0 ±  
144.1 
0.0 (0.0 - 1240.2) 1.6 38.8 ± 310.1 0.0 (0.0 - 2480.4) 0.741 
Total 91.6 
 3659.1 ± 
5913.8 



















             
Moisturising creams  90.3 
1083.7 ± 
1706.2 















885.9 (0.0 - 
6644.0) 
0.009 
Hygiene products  78.6 
647.8 ± 
969.1 















442.9 (0.0 - 
10630.3) 
0.027 
Extra laundry 22.2 
169.3 ± 
527.6 





0.0 (0.0 - 4429.3) 24.8 
141.1 ± 
391.1 
0.0 (0.0 - 2214.7) 26.6 303.0 ± 689.0 0.0 (0.0 - 2657.6) 0.3227 
Clothing and textiles 16.2 
182.8 ± 
715.1  





0.0 (0.0 - 8858.6) 18 
215.8 ± 
800.4 
0.0 (0.0 - 6644.0) 23.4 
382.6 ± 
1011.4 









0.0 (0.0 - 13287.9) 15 
121.5 ± 
582.7  
0.0 (0.0 - 4429.3) 17.2 
312.6 ± 
1543.0 
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Water filter 9.6 
218.4 ± 
2180.3  
0.0 (0.0 – 
44293.0) 
7 73.3 ± 467.4 0.0 (0.0 - 6644.0) 14.3 
223.5 ± 
1583.7 
0.0 (0.0 - 17717.2) 12.5 
924.2 ± 
5628.0 
0.0 (0.0 - 44293.0) 0.040 
Special diet 11.7 
282.9 ± 
1220.4 





0.0 (0.0 - 17717.2) 10.5 
214.9 ± 
957.1  
0.0 (0.0 - 8858.6) 17.2 
493.2 ± 
1409.1 




0.0 (0.0 – 
53151.6) 
5.1 65.9 ± 550.2 0.0 (0.0 - 8858.6) 3 16.3 ± 106.1 0.0 (0.0 - 1022.2) 9.4 
1241.3 ± 
6997.1 
0.0 (0.0 - 53151.6) 0.143 
Total 92.2 
 2934.6 ± 
6236.3 















2274.3 (0.0 - 
75121.0) 
<0.001 
Combined total    
7942.6 ± 
9595.4 















7881.9 (1144.0 – 
79381.3) 
<0.001 
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Table 3. Time (hours) spent on informal caregiving per week by AD severity 
 Activity         Total (n=513) 
Hours per week  

















(min - max)  
Personal care 4.6 ± 7.5 
2.0 (0.0 – 
84.0) 
4.1 ± 6.8 
2.0 (0.0 – 
50.0) 
4.9 ± 6.5 
2.0 (0.0 – 
42.0) 
6.2 ± 11.6 
3.0 (0.0 – 
84.0) 
0.202 
Accompanying to healthcare visits* 0.6 ± 2.1  
0.0 (0.0 – 
27.6) 
0.5 ± 1.9 
0.0 (0.0 – 
27.6) 
0.8 ± 2.9 
0.0 (0.0 – 
27.0) 
0.6 ± 1.2 
0.0 (0.0 – 
5.5) 
0.026 
Companionship &emotional support 3.4 ± 9.3 
0.0 (0.0 – 
112.0) 
2.8 ± 7.5 
0.0 (0.0 – 
56.0) 
3.6 ± 7.0 
0.2 (0.0 – 
56.0) 
6.6 ± 17.6 
0.0 (0.0 – 
112.0) 
0.040 
Specially prepared homemade food 1.7 ± 5.2  
0.0 (0.0 – 
72.0) 
1.8 ± 5.9 
0.0 (0.0 – 
72.0) 
1.5 ± 4.0 
0.0 (0.0-
28.0) 
1.7 ± 3.8 
0.0 (0.0 – 
21.0) 
0.573 
Other additional housework activities 0.1 ± 0.7  
0.0 (0.0 – 
14.0) 
0.1 ± 0.8 
0.0 (0.0 – 
14.0) 
0.1 ± 0.4 
0.0 (0.0 – 
3.5) 
0.1 ± 0.9 
0.0 (0.0 – 
7.0) 
0.741 
Total  10.3 ± 16.7 
4.5 (0.0 – 
133.0) 
9.2 ± 16.1 
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Table 4.Factors associated with the annual total costs (healthcare, informal caregiving 
and out-of-pocket expenses in US$) for children with atopic dermatitis using generalised 
linear model 
Variables 
Univariable analysis Multivariable analysis 
Coeff. SE p-value Coeff. SE p-value 
Age of children (years) -0.01 0.01 0.451 -0.07 0.01 <0.001 
Gender 





Male -0.04 0.11 0.707 -0.15 0.92 0.114 
Ethnic group 





Malay 0.31 0.13 0.014 0.31 0.12 0.010 
Indian 0.39 0.28 0.155 0.36 0.24 0.128 
Others 0.75 0.29 0.009 0.42 0.15 0.005 
Duration of disease (years) 0.03 0.02 0.055 0.06 0.02 <0.001 
AD severity 





Moderate 0.18 0.11 0.104 0.28 0.10 0.007 
Severe 0.77 0.16 <0.001 0.94 0.16 <0.001 
Responder's education 
      




Secondary school or lower  -0.09 0.15 0.562 -0.14 0.13 0.302 
University -0.17 0.13 0.195 -0.16 0.12 0.184 
Responder's employment 





Employed -0.14 0.14 0.326 -0.36 0.12 0.754 
Accommodation 
      




4-5 bedroom HDB -0.14 0.14 0.344 -0.10 0.11 0.380 
Condominium/landed property -0.18 0.20 0.366 -0.20 0.15 0.203 
Ref.: reference category; Coeff.: coefficient; SE: standard error 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
